Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
16-30 of 231
The Critical Next Steps After Subarachnoid Hemorrhage Diagnosis
NeuroFrontiersThe Critical Next Steps After Subarachnoid Hemorrhage Diagnosis
Jay Max Findlay
Spotting the Warning Signs of Subarachnoid Hemorrhage
NeuroFrontiersSpotting the Warning Signs of Subarachnoid Hemorrhage
Jay Max Findlay
The Recovery Trajectory of Subarachnoid Hemorrhage
NeuroFrontiersThe Recovery Trajectory of Subarachnoid Hemorrhage
Jay Max Findlay
Evaluating Delayed Presentations of Subarachnoid Hemorrhage
NeuroFrontiersEvaluating Delayed Presentations of Subarachnoid Hemorrhage
Jay Max Findlay
Mobilization Outcomes After Aneurysmal Subarachnoid Hemorrhage
NeuroFrontiersMobilization Outcomes After Aneurysmal Subarachnoid Hemorrhage
Consensus-Driven Outcomes for Aneurysmal Subarachnoid Hemorrhage Research
NeuroFrontiersConsensus-Driven Outcomes for Aneurysmal Subarachnoid Hemorrhage Research
- advertisement
How Real-World Adherence Is Shaping Preventive Migraine Treatment
NeuroFrontiersHow Real-World Adherence Is Shaping Preventive Migraine Treatment
Alexandria May, PharmD, BCPS
Jessica Ailani, MD, FAHS, FAAN, FANA
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
NeuroFrontiersRecognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Alexandria May, PharmD, BCPS
Kaitlin Batley, MD
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
NeuroFrontiersIdentifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Charles Turck, PharmD, BCPS, BCCCP
Bethany Lussier, MD
FXIa Remix! Keeping the Flow Without Missing a Beat
CME/CEFXIa Remix! Keeping the Flow Without Missing a Beat
Mike Sharma, MD, MSc, FRCPC
Ashkan Shoamanesh, MD
Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA
Understanding Variability in Myasthenia Gravis
NeuroFrontiersUnderstanding Variability in Myasthenia Gravis
Henry Kaminski, MD
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiersExamining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP
Austin Larson, MD
- advertisement
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
NeuroFrontiersMicroglia Drive Neurodegeneration in Friedreich’s Ataxia
Ryan Quigley
MS in Women: How Life Stages Shape Treatment Decisions
NeuroFrontiersMS in Women: How Life Stages Shape Treatment Decisions
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiersUnpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
